首页> 外国专利> COMPOSITIONS FOR USE IN TREATING AUTOSOMAL DOMINANT BEST1-RELATED RETINOPATHIES

COMPOSITIONS FOR USE IN TREATING AUTOSOMAL DOMINANT BEST1-RELATED RETINOPATHIES

机译:用于治疗常染色体占优势的组合物与营养素有关的患者

摘要

The present invention refers to a sgRNA molecule comprising a targeting domain for specifically targeting a SNP in the BEST1 coding region of a pathologic allele, wherein said targeting domain consists of a sequence selected from the group consisting of SEQ ID NO: 3- 8, 41-44, 14-20, 50-52 and 54-55, or a sgRNA molecule combination of specifically defined first and second sgRNA molecules, wherein the first and the second sgRNA molecule each comprise a targeting domain for specifically targeting a SNP in the BEST1 gene coding or non- coding region of a pathologic allele. The present invention also refers to a nucleic acid comprising a sequence that encodes the sgRNA molecule or sgRNA molecule combination and to nucleic acid combinations. The present invention further relates to a recombinant adenovirus- associated virus (AAV) comprising the nucleic acids according to the present invention or recombinant AAV combinations. The sgRNA molecule, the nucleic acid, the recombinant AAV and combinations are useful tools for editing of the target domain in the bestrophin-1 (BEST1) gene to restore BEST1 channel function by e.g. CRISPR/Cas9-based gene editing. The present invention further relates to the sgRNA molecule, the sgRNA molecule combination, the nucleic acid, the nucleic acid combination, the recombinant AAV and the recombinant AAV combination for use in a method for treatment of the human or animal body by surgery or therapy and for use in method of treating or preventing BEST1-related retinopathies, in particular autosomal dominant BEST1-related retinopathies.
机译:本发明涉及包含用于特异性靶向病理等位基因的BEST1编码区域中的SNP的靶向域的SGRNA分子,其中所述靶向域由选自SEQ ID NO:3-8,41中的组中选择的序列组成-44,14-20,50-52和54-55,或特异性限定的第一和第二SGRNA分子的SGRNA分子组合,其中第一和第二SGRNA分子各自包含靶向结构域,用于特别靶向最佳的SNP病理等位基因的基因编码或非编码区域。本发明还指的是包含编码SGRNA分子或SGRNA分子组合和核酸组合的序列的核酸。本发明还涉及包含根据本发明或重组AAV组合的核酸的重组腺病毒相关病毒(AAV)。 SGRNA分子,核酸,重组AAV和组合是用于编辑营养蛋白-1(BEST1)基因中的靶结构域以通过例如恢复最佳的通道功能的有用工具。基于CRISPR / CAS9的基因编辑。本发明还涉及SGRNA分子,SGRNA分子组合,核酸,核酸组合,重组AAV和重组AAV和重组AAV组合用于通过手术或治疗治疗人体或动物体的方法用于治疗或预防最佳相关的视网膜病变的方法,特别是常染色体优势最佳的相关视网膜病变。

著录项

  • 公开/公告号WO2021214066A1

    专利类型

  • 公开/公告日2021-10-28

    原文格式PDF

  • 申请/专利权人 UNIVERSITÄT REGENSBURG;

    申请/专利号WO2021EP60253

  • 发明设计人 WEBER BERNHARD;MILENKOVIC ANDREA;

    申请日2021-04-20

  • 分类号C12N15/113;A61K48;A61P27;C12N9/22;

  • 国家 EP

  • 入库时间 2022-08-24 21:59:59

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号